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Table
Baseline demographics and clinical characteristics of participants and pre-





baseline at 14 weeks
(n¼7) P-value*
Age, years 71.9 (65.4) N/A N/A
Gender, f/m 6/2 N/A N/A
MMSE # 24.3 (64.4) -1.4 (63.3) 0.3
SDMT 90 sec # 17.4 (64.0) -3.1 (63.5) 0.06
SDMT 120 sec # 22.9 (65.3) -4.4 (64.1) 0.03
QoL-AD patient # 37.4 (65.7) 0.4 (62.9) 0.7
QoL-AD proxy # 39.3 (65.7) -3.4 (61.7) 0.002
ADCS-ADL # 69.6 (65.5) -3.1 (65.7) 0.19
GDS-15 x 3.1 (62.2) -1 (61) 0.04
*Paired-samples t-test
# Higher score¼better function, x Lower score¼better function
Poster Presentations: P4P716were included in the study (see Table). Attendance (90 %, (70-100 %)) and
retention (87,5 %) rates were high. Two patients experienced knee-pain,
and two falls unrelated to the intervention occurred. Patients had fewer de-
pressive symptoms after the intervention (mean change on GDS: -1, (61);
P ¼ 0.04). Proxy-rated QoL (-3.4 (61.7); P ¼ 0.002) decreased whereas
patient-rated QoL did not (0.4 (62.9); P ¼ 0.7). SDMT score (-4.4
(64.1);P ¼ 0.03)) decreased indicating a worsening of mental speed
and processing. PiB retention increased in all patients (pre-test: 2.60
(60.3); post-test: 2.71 (60.31); P ¼ 0.005), Figure. Patients and care-
givers were positive towards the intervention. Conclusions: It is feasible
and safe to carry out a study of moderate intensity aerobic exercise in
patients with mild to moderate AD, and the intervention may decrease
depressive symptoms. Decline in cognitive function and increase in PiB-
retention also observed is compatible with the natural history of AD.
Our uncontrolled study was not designed to examine the effectiveness of
aerobic exercise which must be evaluated in a large-scale randomized
controlled trial.P4-231 A NOVEL APPROACH FOR LOWERINGMULTIPLE TARGETS IN ALZHEIMER’S DISEASELina Adwan, Nasser Zawia, University of Rhode Island, Kingston, Rhode
Island, United States.
Background: Due to the increase in life expectancy and the absence of
a cure for Alzheimer’s disease (AD), the number of cases with this de-
bilitating disorder is predicted to triple over the next 40 years to 106.8
million worldwide and 13.2 million in the US, with an annual incidence
that will be close to 1 million cases per year in 2050. Current therapeutic
approaches merely target the symptoms of the disease but not its core
pathology, and fail to alter the devastating course of AD that ultimately
leads to terminal memory dysfunction and death. Considering the poor
performance of existing drugs, there is an increasing need to develop al-
ternative therapies that modify the disease process. The amyloid beta
(Ab) plaques and tau neurofibrillary tangles are the characteristic de-
posits found in the AD brain. Ab, which is the main component of
AD plaques, is derived from the amyloid beta precursor protein (APP)
following sequential enzymatic cleavage by beta site APP cleaving en-
zyme (BACE) and g-secretase. Tau belongs to a family of microtubule
associated proteins (MAPs) that promote microtubule assembly. When
hyperphosphorylated, tau loses its normal function and becomes prone
to form aggregates, and increased hyperphosphorylated tau levels in
the brain correlate with memory impairment. We have found an agent
that targets both the amyloid and tau neurofibrillary pathways of AD
through a unique transcription driven mechanism. Methods: Mice wereadministered control or two different treatment doses everyday for one
month by oral gavage. We used real time PCR, Western blot analysis
and enzyme-linked immunosorbent assay (ELISA) for determining
mRNA and protein levels amongst control and treatment brain tissue,
as well as a highly sensitive activity kit to measure BACE1 enzyme ac-
tivity. Results: Our results showed that both tau mRNA and protein
levels were lowered following treatment in mice. BACE1 activity and
levels were also decreased with treatment as well as APP mRNA and
protein, and Ab levels. Conclusions: Thus we present a drug candidate
that inhibits the transcription of multiple major intermediates in AD
pathology and uncovers a new mechanism based approach for targeting
AD.P4-232 NITRIC OXIDE MEDIATES AGMATINE-INDUCEDIMPROVEMENTS IN MEMORYMaryam Moosavi, Atefeh Khajeh, Golnaz Yadollahi Khales, Shiraz
University of Medical Sciences, Shiraz, Iran.
Background: Agmatine (4-aminobutyl guanidine) is one of the metabo-
lites of L-arginine. It is synthesized by arginine decarboxylase (ADC)
and hydrolysed by agmatinase. Agmatine is widely distributed in the
brain and its concentration is similar to the other neurotransmitters con-
centrations. Because agmatine is synthesized in the brain, stored in syn-
aptic vesicles, accumulated by uptake, released by depolarization and
inactivated by agmatinase, it is considered to be a putative neurotrans-
mitter. It is reported recently that agmatine improves memory but its
mechanism of action is not elucidated yet. Agmatine is suggested to
modulate nitric oxide synthesis by affecting nitric oxide synthase
(NOS); it inhibits neuronal (nNOS) and inducible (iNOS) NOS, while
stimulates endothelial (eNOS) type and elevates nitric oxide (NO) and
cyclic GMP levels. NO is the key link between NMDA-mediated in-
creases in cytoplasmic Ca 2+, LTP and synaptic plasticity which are es-
sential for memory formation. Then the aim of this study was to assess if
nitric oxide synthesis inhibition prevents agmatine improving effect on
memory. Methods: Adult male Sprague-Dawely rats weighing 200-
300 g were trained in a single session consisting of 8 trials. The probe
test was done 24 hours later to assess memory retention. Saline, agma-
tine (40 mg/kg) and/or L-NAME (3 mg/kg) was administered immedi-
ately after training. While agmatine improved animals’ performance
in probe trial, L-NAME prevented that improving effect. Results: The
results showed that L-NAME (the inhibitor of nitric oxide synthesis) pre-
vents agmatine-induced improving effect on memory. Conclusions: It
seems that nitric oxide is involved in agmatine-induced memory
improvement.P4-233 DONEPEZIL IN THE TREATMENT OFALZHEIMER’S DISEASE: RESULTS FROM
A ROUTINE CLINICAL PRACTICE SETTINGSaid Ramdane, Private Office of Neurology, Algerian Society of Neurology
and Clinical Neurophysiology, Skikda, Algeria.
Background: Clinical experience provides useful complement to the ev-
idence available from clinical trials. We evaluated safety and effective-
ness of Donepezil in a sample of elderly patients with Alzheimer’s
disease, in routine clinical practice. Methods: This was a retrospective
case note study involving patients with mild-moderate Alzheimer’s dis-
ease, followed in a clinical ambulatory of neurology (2008-2011), re-
cruited in community elderly (Skikda-Algeria). Among the patients who
matched the prescribing recommendations for donepezil, 47 patients
(59% female; mean 6SD age, 75.668.6 years) completed 12 months do-
nepezil treatment (5 to10 mg/day). Efficacy and safety assessments were
carried out every 3 months. Efficacy was assessed by the Mini-Mental
State Examination (MMSE), Neuropsychiatric Inventory Questionnaire
(NPI-Q), Katz Index of Independence in Activities of Daily Living
